Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy.

person Evangelos Terpos National and Kapodistrian University of Athens, Athens, Greece info_outline Evangelos Terpos, Barbara Gamberi, Jo Caers, Maaike Söhne, Sonja Heibl, Florence Suzan, Zsolt Szabo, Abeera Mohammad, Sally Wetten, Xavier Leleu

Authors person Evangelos Terpos National and Kapodistrian University of Athens, Athens, Greece info_outline Evangelos Terpos, Barbara Gamberi, Jo Caers, Maaike Söhne, Sonja Heibl, Florence Suzan, Zsolt Szabo, Abeera Mohammad, Sally Wetten, Xavier Leleu Organizations National and Kapodistrian University of Athens, Athens, Greece, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Department of Hematology, CHU de Liège, Liège, Belgium, St Antonius Hospital, Nieuwegein, Netherlands, Klinikum Wels-Grieskirchen GmbH, Wels, Austria, Amgen (Europe) GmbH, Rotkreuz, Switzerland, Amgen Ltd, Uxbridge, United Kingdom, CHU de Poitiers, Poitiers, France Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Background: To understand how novel therapies approved in relapsed multiple myeloma, e.g. carfilzomib (CFZ), are used in real-life, we describe the results of a planned interim analysis from a large observational study (NCT03091127). Methods: The study enrolled adult patients (pts) who received ≥1 prior line of therapy and ≥1 CFZ dose in routine care. Pts were followed until 30 days after last CFZ dose or up to 18 months (mos) from initiation. Results: As of 22 Oct 2018, 293 pts from 10 included EU countries were observed for a median time of 7 mos. At CFZ initiation, pts who received CFZ, lenalidomide and dexamethasone (KRd) were younger than pts treated with CFZ and dexamethasone alone (Kd): 64 vs 70 years (median), respectively. Over half of KRd pts had received 1 prior line of therapy while nearly half of Kd pts had ≥4 prior lines. Hypertension (30%), cardiac disorder (14%), diabetes (12%) and renal disorder (9%) were reported at CFZ initiation. A best response (see Table) was achieved in 3-4 mos. The total dose received relative to EU label on average was 95% and 74% by KRd (20/27 mg/m 2 for K) and Kd pts (20/56 mg/m 2 for K), respectively. The Kaplan-Meier median estimate of treatment duration was 16.6 mos for KRd and 7.7 mos for Kd pts. Among the 138 pts who discontinued, disease progression/refractoriness was the most frequent reason (40%). Gr3+ AEs were reported in 37% pts, including hypertension (2%) and cardiac failure (1%). Conclusions: In this real-life setting, KRd pts are younger and receive CFZ in earlier lines than Kd pts and the benefit-risk profile is consistent with published trials. The estimated treatment duration was longer than observed in other real-life data. Response by planned carfilzomib (K) regimen. Rd (N = 178) Kd (N = 93) Other K Regimens a (N = 22) Age, median years (min, max) 64 (32, 87) 70 (45, 92) 65 (44,79) Number of prior lines of therapy, median (min, max) 1 (1, 8) 3 (1, 9) 3 (1, 6) Pts with evaluable best response, n: 142 66 17 CR or better, n (%) 32 (22.5) 5 (7.5) 6 (35.3) VGPR, n (%) 55 (38.7) 19 (28.8) 5 (29.4) PR, n (%) 27 (19.0) 17 (25.8) 1 (5.9) Overall response rate (PR or better), n (%) 114 (80.2) 41 (62.1) 12 (70.6) a includes triplets with cyclophosphamide, pomalidomide, bendamustine, daratumumab, thalidomide, or elotuzumab